Cellectis develops gene-editing technologies and cell therapies to treat cancers of the blood, myeloid, and lymphatic systems. The Raleigh location is the company's GMP manufacturing plant for Cellectis' portfolio of UCART drug products.
Company Location
2500 Sumner Blvd.
Raleigh
NC
27616
Phone
984-477-9025
County
Region
Company Details
Company type
Year founded
1999
Employment range in NC
US headquarters
North Carolina
Global headquarters
France
Primary site activity
All company activities
Core capabilities
Potential end market(s)
Products under development
Immunotherapies based on gene-edited allogeneic CAR T-cells: UCART22 (B-ALL); UCART123 (AML); UCARTCS1 (MM); UCART20x22 (NHL)